Background: Ticagrelor is a widely used oral P2Y12 receptor antagonist administered after percutaneous coronary intervention (PCI) as part of dual antiplatelet therapy. Drug-induced liver injury (DILI) is a rare but clinically important adverse effect that is under-recognised because of its low incidence and diagnostic overlap with other causes of hepatocellular and cholestatic injury. Case Summary: We report a 61-year-old woman who underwent uncomplicated PCI and was discharged on dual antiplatelet therapy with ticagrelor and aspirin, together with a statin. Approximately nine weeks later, routine follow-up investigations revealed markedly deranged liver function tests (total bilirubin 7.5 mg/dL, ALT 892 IU/L, AST 768 IU/L, ALP 1220 IU/L) with no biochemical or clinical evidence of biliary obstruction on cross-sectional imaging. The statin was withdrawn immediately upon recognition. A comprehensive work-up — viral hepatitis serology (HAV, HBV, HCV, HEV), dengue NS1, Leptospira serology, autoimmune liver panel (ANA, LKM-1, soluble liver antigen), and abdominal imaging — did not identify an alternative cause. Given the absence of another explanation and the temporal association with drug exposure, ticagrelor was discontinued nine days after the abnormality was first detected. Liver enzymes and bilirubin subsequently trended downward. Causality assessment using the Roussel Uclaf Causality Assessment Method (RUCAM) yielded a score of 4, corresponding to a "possible" drug-induced hepatic injury attributable to ticagrelor. Conclusion: Clinicians should maintain a high index of suspicion for ticagrelor-induced hepatotoxicity in patients presenting with unexplained liver injury after PCI, even when a more commonly implicated agent such as a statin is also present. Early recognition, systematic exclusion of alternative aetiologies, and timely drug withdrawal are key to a favourable outcome.
Ticagrelor is a reversibly-binding, direct-acting P2Y12 receptor antagonist recommended alongside aspirin as dual antiplatelet therapy following percutaneous coronary intervention (PCI) for acute coronary syndrome. Its efficacy in reducing recurrent ischaemic events is well established; however, its hepatic safety profile has been less extensively characterised than that of thienopyridines such as clopidogrel. Drug-induced liver injury (DILI) associated with antiplatelet agents is uncommon, and when it occurs it is more frequently reported with clopidogrel than with ticagrelor, with only a small number of ticagrelor-associated cases described in the literature to date.
The diagnosis of DILI remains one of exclusion, requiring systematic elimination of viral, autoimmune, biliary, infective and ischaemic causes of liver injury before a drug can be implicated. The Roussel Uclaf Causality Assessment Method (RUCAM) provides a structured, semi-quantitative framework for this purpose and is the most widely used causality scale in DILI case reports. We describe a case of clinically significant cholestatic-pattern liver injury temporally associated with ticagrelor use following PCI, in which a concomitantly prescribed statin — a more classically hepatotoxic agent — had already been withdrawn without arresting the biochemical deterioration, before ticagrelor was identified as the more probable culprit.
A 61-year-old woman with coronary artery disease underwent percutaneous coronary intervention (PCI) on 23 April 2026. Post-procedure 2D-echocardiography confirmed a good result with preserved left ventricular systolic function (ejection fraction 62%), no regional wall motion abnormality, and no pericardial effusion or intracardiac thrombus. She was discharged on dual antiplatelet therapy (ticagrelor 90 mg twice daily and aspirin), a statin, and standard secondary-prevention medications.
She remained clinically well until a routine outpatient review approximately nine weeks later, on 30 June 2026, when blood investigations incidentally revealed marked derangement of liver function: total bilirubin 7.5 mg/dL (direct 5.1, indirect 2.4), ALT 892 IU/L, AST 768 IU/L, and alkaline phosphatase 1220 IU/L, with preserved synthetic function (albumin 3.5 g/dL, INR 1.2). She was admitted the same day for further evaluation. The statin was withdrawn immediately as the initial presumptive hepatotoxic agent, given its established association with drug-induced liver injury.
Over the following days, bilirubin and transaminases continued to fluctuate at markedly elevated levels despite statin cessation (peak total bilirubin 8.0 mg/dL and peak ALP 1257 IU/L on hospital day 3–4), prompting a broader diagnostic work-up (detailed below). No alternative cause was identified. Given the absence of another explanation and the temporal relationship to continued drug exposure, ticagrelor was discontinued on 4 July 2026 — nine days after the hepatic abnormality was first detected — and was substituted with an alternative antiplatelet strategy per the treating cardiology team. Liver enzymes and bilirubin subsequently showed a consistent downward trend (Table 1).
The patient had no history of alcohol use, no new over-the-counter or herbal medication use, no recent travel, and no risk factors for viral hepatitis. She denied pruritus, abdominal pain, fever, or pale stools. Physical examination revealed mild icterus without stigmata of chronic liver disease, hepatomegaly, or ascites.
Table 1 summarises the trend of liver biochemistry from the day of first detection of abnormal values (30 June 2026) through five days after ticagrelor discontinuation (5 July 2026).
Table 1. Trend of liver function tests.
| Parameter (normal range) | 30 Jun 2026 | 2 Jul 2026 | 3 Jul 2026 | 5 Jul 2026 |
| Total bilirubin (0.3–1.2 mg/dL) | 7.5 | 8.0 | 6.9 | 3.8 |
| Direct bilirubin (0.0–0.2 mg/dL) | 5.1 | 5.5 | 4.7 | 2.7 |
| ALT / SGPT (7–35 IU/L) | 892 | 723 | 592 | 411 |
| AST / SGOT (15–41 IU/L) | 768 | 510 | 329 | 194 |
| Alkaline phosphatase (32–91 IU/L) | 1220 | 1046 | 1257 | 987 |
| Albumin (3.5–5.0 g/dL) | 3.5 | 3.3 | 3.4 | 3.3 |
| INR | 1.20 | 1.25 | 1.25 | 1.00 |
Additional work-up to exclude alternative causes of liver injury included:
The R-ratio, calculated at the time of first biochemical detection using ALT 892 IU/L (ULN 35) and ALP 1220 IU/L (ULN 91), was 1.9 [(892/35) ÷ (1220/91)], indicating a cholestatic pattern of injury (R < 2). The cholestatic/ALP-based RUCAM domains were therefore applied (Table 2).
Table 2. RUCAM causality assessment for ticagrelor.
| Domain | Finding in this patient | Score |
| 1. Time to onset from start of ticagrelor | Ticagrelor started 23 Apr 2026; abnormal LFTs first detected 30 Jun 2026 (≈68 days). Suggestive range for cholestatic injury is 5–90 days. | +2 |
| 2. Course after cessation of ticagrelor | ALP fell from 1257 IU/L (3 Jul) to 987 IU/L (5 Jul), a 21.5% decrease within 2 days of stopping the drug (<50% decrease within the assessment window). | +1 |
| 3. Risk factors | Age ≥55 years (+1); no documented alcohol use (0). | +1 |
| 4. Concomitant drug(s) | Statin was co-administered from the time of PCI and is a recognised hepatotoxin with compatible/suggestive onset timing; it was withdrawn on 30 Jun 2026 but liver injury persisted and worsened afterward, which argues against the statin as the sole cause but the RUCAM scale still penalises the presence of a competing hepatotoxic drug. | −2 |
| 5. Exclusion of other causes | All Group I causes excluded: HAV, HBV, HCV IgM/serology negative; imaging showed no biliary obstruction; no alcohol history; no recent hypotensive/ischaemic episode. Group II causes (CMV, EBV, HSV) not specifically tested. | +1 |
| 6. Previous hepatotoxicity information | Ticagrelor-associated hepatotoxicity has been previously reported in the literature (case reports), though it is not a widely recognised labelled adverse effect. | +1 |
| 7. Response to re-administration | Rechallenge was not performed for safety reasons. | 0 |
| Total RUCAM score | 4 |
Interpretation: A total RUCAM score of 4 falls within the range of 3–5, corresponding to a "possible" causal relationship between ticagrelor and the observed liver injury. This is presented as a working estimate based on the available records; the treating clinical team should confirm each domain against the complete case file, and Group II infective causes (CMV, EBV, HSV) should ideally be tested to allow the exclusion-of-other-causes domain to be scored with full confidence
Drug-induced liver injury remains a diagnosis of exclusion, and post-PCI patients present a particular challenge because they are typically prescribed several agents with recognised hepatotoxic potential simultaneously — most commonly statins, but also clopidogrel, ticagrelor, and occasionally proton-pump inhibitors. In this patient, the statin was the first agent withdrawn, reflecting its well-established association with hepatocellular and mixed-pattern liver injury. However, the persistence and further worsening of cholestatic parameters after statin withdrawal, together with a comprehensive negative work-up for viral, autoimmune, infective and obstructive causes, redirected clinical suspicion toward ticagrelor, which was withdrawn nine days after the abnormality was first noted.
Ticagrelor-induced hepatotoxicity is rare and has been described only in isolated case reports, in contrast to the comparatively better-characterised hepatotoxic profile of clopidogrel, which has been reported to cause a cholestatic or mixed hepatitis typically presenting within 2 to 24 weeks of drug initiation. The mechanism of ticagrelor-associated liver injury is not well established but is presumed to be idiosyncratic, similar to other P2Y12 inhibitors. The R-ratio of 1.9 in this case places the injury pattern at the cholestatic end of the spectrum, which is broadly consistent with the pattern described in the limited published literature on ticagrelor hepatotoxicity.
A modestly positive ANA with a cytoplasmic fibrillar pattern (titre 1:160) was noted, together with a mildly raised CRP, ammonia and LDH. In isolation, these findings do not fulfil criteria for autoimmune hepatitis (negative anti-LKM-1 and soluble liver antigen antibodies), and low-titre ANA positivity is a recognised non-specific finding in patients with acute hepatocellular injury from any cause, including DILI. Similarly, the equivocal Leptospira IgM in a patient without a compatible exposure history or clinical syndrome (fever, myalgia, conjunctival suffusion) was considered unlikely to represent acute leptospirosis, though the recommended convalescent-phase retesting had not been performed at the time of this report.
The RUCAM score of 4 ("possible" causality) in this case is limited chiefly by two factors: the presence of a competing hepatotoxic drug (the statin) taken concomitantly, and the short duration of post-cessation follow-up data available at the time of this report, which restricts full scoring of the dechallenge domain. A higher score would be anticipated with (a) demonstration of a greater than 50% fall in ALP on longer follow-up, and (b) exclusion of Group II infective causes (CMV, EBV, HSV serology). Notably, statin discontinuation alone, five days prior to ticagrelor withdrawal, did not arrest the biochemical deterioration — biochemical worsening actually continued for several days after the statin was stopped and only reversed after ticagrelor was also withdrawn — which is a clinically important observation supporting a meaningful contribution from ticagrelor rather than the statin alone.
This case underscores the importance of considering ticagrelor as a possible cause of unexplained liver injury in post-PCI patients, even when a more classically hepatotoxic co-prescribed agent such as a statin has already been discontinued without biochemical improvement. Prompt recognition and drug withdrawal, guided by a systematic causality framework such as RUCAM, remain central to management, given the absence of a specific antidote for antiplatelet-associated DILI.
We describe a case of cholestatic-pattern liver injury temporally associated with ticagrelor use following PCI, assessed as "possible" drug-induced liver injury (RUCAM score 4) after systematic exclusion of viral, autoimmune, infective and obstructive causes. Clinicians managing post-PCI patients on dual antiplatelet therapy should be aware that ticagrelor, not only the concomitantly prescribed statin, can be a contributing or primary cause of unexplained hepatic dysfunction, and that failure to improve after withdrawal of the more traditionally suspected agent should prompt reconsideration of the antiplatelet agent itself.